Albert Lowe
Stock Analyst at Craig-Hallum
(3.40)
# 868
Out of 5,242 analysts
11
Total ratings
36.36%
Success rate
48.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRB Spruce Biosciences | Initiates: Buy | $140 | $51.52 | +171.77% | 1 | Apr 27, 2026 | |
| PVLA Palvella Therapeutics | Initiates: Buy | $175 | $115.50 | +51.52% | 1 | Dec 4, 2025 | |
| NGNE Neurogene | Initiates: Buy | $50 | $26.95 | +85.53% | 1 | Jun 17, 2025 | |
| ATOS Atossa Therapeutics | Initiates: Buy | $20 | $4.84 | +313.22% | 1 | Jun 5, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $6 | $4.44 | +35.14% | 1 | Apr 11, 2025 | |
| SKYE Skye Bioscience | Maintains: Buy | $18 → $14 | $0.769 | +1,720.55% | 2 | Mar 21, 2025 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $11 | $3.68 | +198.91% | 1 | Oct 9, 2024 | |
| CRDF Cardiff Oncology | Initiates: Buy | $8 | $1.84 | +334.78% | 1 | Sep 6, 2024 | |
| LCTX Lineage Cell Therapeutics | Initiates: Buy | $4 | $1.29 | +210.08% | 1 | Aug 20, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $6 | $1.31 | +358.02% | 1 | May 13, 2024 |
Spruce Biosciences
Apr 27, 2026
Initiates: Buy
Price Target: $140
Current: $51.52
Upside: +171.77%
Palvella Therapeutics
Dec 4, 2025
Initiates: Buy
Price Target: $175
Current: $115.50
Upside: +51.52%
Neurogene
Jun 17, 2025
Initiates: Buy
Price Target: $50
Current: $26.95
Upside: +85.53%
Atossa Therapeutics
Jun 5, 2025
Initiates: Buy
Price Target: $20
Current: $4.84
Upside: +313.22%
Opus Genetics
Apr 11, 2025
Initiates: Buy
Price Target: $6
Current: $4.44
Upside: +35.14%
Skye Bioscience
Mar 21, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $0.769
Upside: +1,720.55%
SAB Biotherapeutics
Oct 9, 2024
Initiates: Buy
Price Target: $11
Current: $3.68
Upside: +198.91%
Cardiff Oncology
Sep 6, 2024
Initiates: Buy
Price Target: $8
Current: $1.84
Upside: +334.78%
Lineage Cell Therapeutics
Aug 20, 2024
Initiates: Buy
Price Target: $4
Current: $1.29
Upside: +210.08%
PMV Pharmaceuticals
May 13, 2024
Initiates: Buy
Price Target: $6
Current: $1.31
Upside: +358.02%